Source: http://www.thefederalregister.com/d.p/2000-11-14-00-29109
Timestamp: 2013-05-21 07:48:23
Document Index: 708645182

Matched Legal Cases: ['art 7114', 'art 3944', 'art 6726', 'art 140', 'art 5250', 'art 1739', 'art 30206', 'art 514', 'art 9740', 'art 180']

Medical devices—; Drugs of abuse; over the counter screening tests;
14 CFR Part 7114 CFR Part 3944 CFR Part 6726 CFR Part 140 CFR Part 5250 CFR Part 1739 CFR Part 30206 CFR Part 514 CFR Part 9740 CFR Part 180	Federal Register: November 14, 2000 (Volume 65, Number 220)
DOCID: FR Doc 00-29109
Docket ID: [Docket No. 99D-1020]
SUBJECT CATEGORY: Medical Devices Draft Guidance on Over the Counter (OTC) Screening Tests for Drugs of Abuse: Guidance for Premarket Notifications; Availability DATES: Submit written comments on the draft guidance by February 12, 2001.
DOCUMENT SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled ``Over the Counter (OTC) Screening Tests for Drugs of Abuse: Guidance for Premarket Notifications.'' FDA is issuing this draft guidance to provide information about studies and labeling considerations applicable to OTC screening tests that use urine as the clinical specimen for any combination of one or more of these drugs: Amphetamine (and, or methamphetamine), cocaine, cannabinoids, opiates, and phencyclidine. This draft guidance defines OTC use for the purposes of this document as use in home, workplace, insurance, and sports settings, and includes requests for comments on confirmatory testing and OTC alcohol testing. This draft guidance is neither final nor in effect at this time.
SUMMARY: Medical devices—; Drugs of abuse; over the counter screening tests; premarket notifications, SUPPLEMENTAL INFORMATION
I. Background In the Federal Register of December 30, 1998 (63 FR 71932), FDA announced the availability for comment of a draft guidance entitled ``Guidance for Premarket Submissions for Tests for Screening Drugs of Abuse to Be Used By The Consumer.'' FDA invited interested persons to comment on the draft guidance by March 30, 1999. FDA is replacing that draft guidance document with a new draft guidance entitled ``Over the Counter (OTC) Screening Tests for Drugs of Abuse: Guidance for Premarket Notifications.'' This second draft guidance provides more detailed recommendations on what to include in a premarket notification for this device, and includes new information addressing the relevant least burdensome provisions of the Food and Drug Administration Modernization Act of 1997. The draft guidance recommends including in the premarket notification:
OTC studies showing correct results at concentrations 50 percent above and 50 percent below the cutoff; Description of the patient reporting format; Studies on the stability of the device; and The confirmatory laboratory's credentials. The draft guidance also seeks public comment on premarket review of OTC alcohol tests. The draft guidance also addresses labeling for these devices.
As part of its efforts to ensure that FDA considers the least burdensome path to market, the agency has drafted the guidance to:
Clarify that OTC screening tests for drugs of abuse ordinarily will be reviewed as a premarket notification;
Suggest the use of spiked urine samples instead of urine obtained from individuals using drugs; and
Suggest combining drugs in these spiked urine samples in order to reduce the number of samples tested.
This draft guidance represents the agency's current thinking on submissions for OTC screening tests for drugs of abuse. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the applicable statute, regulations, or both.
The agency has adopted good guidance practices (GGP's), and published the final rule, which set forth the agency's policies and procedures for the development, issuance, and use of guidance documents (65 FR 56468, September 19, 2000). This guidance document is issued as a Level 1 guidance consistent with the GGP's.
In order to receive the draft guidance entitled ``Over the Counter (OTC) Screening Tests for Drugs of Abuse: Guidance for Premarket Notifications'' via your fax machine, call the CDRH FactsOnDemand system at 8008990381 or 3018270111 from a touchtone telephone. Press 1 to enter the system. At the second voice prompt press 1 to order a document. Enter the document number (2209) followed by the pound sign (#). Follow the remaining voice prompts to complete your request. Persons interested in obtaining a copy of the guidance may also do so using the Internet. The Center for Devices and Radiological Health (CDRH) maintains an entry on the Internet for easy access to information including text, graphics, and files that may be downloaded to a personal computer with access to the Internet. Updated on a regular basis, the CDRH home page includes the civil money penalty guidance documents package, device safety alerts, Federal Register reprints, information on premarket submissions (including lists of approved applications and manufacturers' addresses), small manufacturers' assistance, information on video conferencing and electronic submissions, mammography matters, and other deviceoriented information. The CDRH home page may be accessed at http://www.fda.gov/
cdrh. ``Over the Counter (OTC) Screening Tests for Drugs of Abuse: Guidance for Premarket Notifications'' is available at http:// www.fda.gov/cdrh/ode/guidance/2209.pdf.
Interested persons may submit to Dockets Management Branch (address above) written comments regarding this draft guidance by February 12, 2001. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The draft guidance and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. Dated: November 2, 2000. Linda S. Kahan,
[FR Doc. 0029109 Filed 11800; 4:21 pm]
Jean M. Cooper, Center for Devices and Radiological Health (HFZ440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 3015941243.